期刊文献+

Tau蛋白表达与ER阳性乳腺癌紫杉类化疗敏感性的临床分析 被引量:2

Clinical analysis of Tau protein expressions and taxane-based chemo-sensitivity of breast cancer with ER positive
下载PDF
导出
摘要 目的探讨Tau蛋白表达与ER阳性乳腺癌紫杉类化疗敏感性的关系。方法采用Elivison二步法免疫组化检测乳腺癌组织Tau蛋白的表达,统计分析乳腺癌组织Tau蛋白与ER的相关性,及其与含紫杉类方案新辅助化疗疗效的关系。结果 Tau蛋白在乳腺癌组织的表达率为44%(88/200),与ER表达呈正相关(r=0.32,P<0.0001)。Tau蛋白阴性的乳腺癌患者,紫杉类新辅助化疗疗效、病理化疗反应分级和病理完全缓解率均高于Tau蛋白阳性组,差异有统计学意义(P=0.002、P<0.000 1、P<0.000 1),且这种差异在ER阳性分层分析中也存在(P=0.008、P<0.000 1、P<0.000 1),但在ER阴性的乳腺癌患者中不存在(P=1.000、0.623、0.119)。结论乳腺癌组织Tau蛋白表达与ER正相关,检测Tau蛋白表达可作为ER阳性乳腺癌患者选择紫杉类化疗药物的临床依据。 Objective To investigate the relationship between tau protein expressions and taxane-based chemo-sensitivity of breast cancer with estrogen receptor(ER) positive.Methods The expression of tau protein in breast cancer was detected by elivison two-step immunohistochemical methods,and the results were analyzed with the correlation to ER expression and chemo-sensitivity of taxane.Results The expressions of tau protein in breast cancer tissues were 44%(88/200).Tau protein expression was positively correlated with ER expression(r = 0.32,P 0.000 1).The clinical efficacy,Miller-Payne pathological reactive grade and pathologic complete response rate of taxane-containing neoadjuvant chemotherapy in tau negative patients were higher than in tau positive(P = 0.002,P 0.000 1,P 0.000 1).There were significant differences in ER-positive subgroups(P = 0.008,P 0.000 1,P 0.000 1),but no significant differences in ER-negative subgroups(P = 1.000,0.623,0.119).Conclusion Tau protein expression is positively correlated with ER expression in breast cancer.The detection of tau protein expression can be chosen as a clinical basis for taxane-containing chemotherapy in ER-positive breast cancer patients.
出处 《中国医药导报》 CAS 2012年第12期23-25,共3页 China Medical Herald
基金 江西省卫生厅科技计划(20113148) 南昌市科技重点攻关项目(2010洪财企95)
关键词 TAU蛋白 乳腺癌 ER 紫杉类 抗药性 Tau protein Breast cancer Estrogen receptor Taxane Drug resistance
  • 相关文献

参考文献15

  • 1Ogston KN,Miller ID,Payne S. A new histological grading system to assess response of breast cancers to primary chemotherapy:prognostic significance and survival[J].Breast,2003,(05):320-327. 被引量:1
  • 2Rouzier R,Rajan R,Wagner P. Microtubule-associated protein tau:a marker of paclitaxel sensitivity in breast cancer[J].Proceedings of the National Academy of Sciences(USA),2005,(23):8315-8320. 被引量:1
  • 3Hammond ME,Hayes DF,Dowsett M. American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer[J].Journal of Clinical Oncology,2010,(16):2784-2795. 被引量:1
  • 4Sledge GW,Neuberg D,Bernardo P. Phase Ⅲ trial of doxorubicin,paclitaxel,and the combination of doxorubicin and paclitaxel as frontline chemotherapy for metastatic breast cancer:an intergroup trial(E1193)[J].Journal of Clinical Oncology,2003,(04):588-592. 被引量:1
  • 5Gajria D,Seidman A,Dang C. Adjuvant taxanes:more to the story[J].Clinical Breast Cancer,2010,(Suppl 2):41-49. 被引量:1
  • 6邓权通,王坤,郑登云.Tau与乳腺癌紫杉醇化疗敏感性关系的研究进展[J].中华乳腺病杂志(电子版),2011,5(3):39-42. 被引量:3
  • 7Roman Rouzier,Radhika Rajan,Peter Wagner. Microtubule-associated protein tau:a marker of paclitaxel sensitivity in breast cancer[J].Proceedings of the National Academy of Sciences(USA),2005,(23):8315-8320. 被引量:1
  • 8Tatiana Spicakova,Maureen M,O'Brien. Expression and silencing of microtubule-associated protein Tau in breast cancer cells[J].Molecular Cancer Therapeutics,2010,(11):2970-2981. 被引量:1
  • 9Ikeda H,Taira N,Hara F. The estrogen receptor influences microtubule-associated protein tau(MAPT)expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells[J].Breast Cancer Research,2010,(03):43. 被引量:1
  • 10Wagner P,Wang B,Clark E. Microtubule Associated Protein(MAP)-Tau:a novel mediator of paclitaxel sensitivity in vitro and in vivo[J].Cell Cycle,2005,(09):1149-1152. 被引量:1

二级参考文献40

  • 1王丕琳,李玉文,尹子毅,张铁,朱强,智迎辉.表柔比星联合紫杉醇对浸润性乳腺癌新辅助化疗临床研究[J].中华肿瘤防治杂志,2007,14(9):698-700. 被引量:5
  • 2Priya R, Stewart J A,Harry D B,et al. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel pro- ject protocols 13-18 and B-27[J]. J Clin Oncol, 2008, 26(5): 778-785. 被引量:1
  • 3Mamounas E P, Bryant J, Lembersky B C, et al. Paclitaxel af ter doxorubiein plus cyclophosphamide as adjuvant chemotherapy for node positive breast cancer: Results from NSABP-B 28[J]. J Clin Oncol, 2005, 23(16) :3686-3696. 被引量:1
  • 4Rouzier R, Rajan R, Wagner P, et al. Microtubule-associated protein tau: a marker of paclitaxeI sensitivity in breast cancer [J]. ProcNatlAcadSciUSA, 2005, 102(23) :8315-8320. 被引量:1
  • 5Mazouni C, Peintinger F, Wan-Kau S, et al. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not ad versely affect patient outeome[J]. J Clin Oncol, 2007,25 (19) : 2650-2655. 被引量:1
  • 6Ikeda H, Taira N, Hara F, et al. The estrogen receptor influ ences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant down regulates MAPT and increases the sensitivity to taxane in breast cancer cells[J]. Breast Cancer Res, 2010,12(3) :R43. 被引量:1
  • 7Andre F, Hatzis C, Anderson K, et al. Mierotubule associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor positive breast cancer[J]. Clin Cancer Res, 2007, 13(7):2061-2067. 被引量:1
  • 8Pusztai L, Jeong J H, Gong Y, et al. Evaluation of microtubule-associated protein-tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial[J]. J Clin Oncol, 2009, 27(26): 4287-4292. 被引量:1
  • 9Andre F, Mazouni C, Liedtke C, et al. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer[J]. Breast Cancer Res Treat, 2008, 108(2):183-190. 被引量:1
  • 10Hess K R, Anderson K, Symmans W F, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paelitaxel and fluorouracil, doxorubiein, and cyclophosphamide in breast cancer [J]. J Clin Oncol, 2006, 24(26):4236-4244. 被引量:1

共引文献7

同被引文献19

  • 1Rouzier R, Ouzier R, Rajan R, et al. Microtubule associated protein tau:a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci U S A,2005,102:8315-8320. 被引量:1
  • 2Rossi G, Denoulet L, Crosti F, et al. A new function of microtubule assocated protein Tau: involvement in chromosome stability. Cell Cycle ,2008,7 : 1788-1794. 被引量:1
  • 3Baquero MT, Hanna JA, Neumeister V,et al. Stathmin expression and its relationship to microtubule-associated protein tau and outcome in breast cancer. Cancer,2012,118:4660 -4669. 被引量:1
  • 4Andre F, Hatzis C, Anderson K, et al. Microtubule associated protein-Tau is a bifunctional predictor of endocr/ne sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. Clin Cancer Res ,2007,13:2061-2067. 被引量:1
  • 5lkeda H, Taira N, Hara F, et al. The estrogen receptor influences microtubule associated protein Tau (MAPT) expression and the selective estrogen receptorinhibitor fulvestrant downregulates MAPT and increases the sensit-ivity to taxane in Breast cancer cells. Breast Cancer Res,2010,12:43. 被引量:1
  • 6Pusztai L, Jeong JH, Gong Y, et al. Evaluation of microtubule associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial. J Clin Oncol, 2009,27:42$%4292. 被引量:1
  • 7Andere F, Mazounl C, Liedtke C, et al. Her-2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in 21 breast cancer. Breast Cancer Res Treat,2008,108 : 183-190. 被引量:1
  • 8Zhang M, Liu HX, Teng XD, et al. The differences in CXCR4 protein expression are significant for the five Molecular subtypes of breast cancer. Ultrastruct Pathol,2012,36:381-386. 被引量:1
  • 9Baquero MT, Lostritto K, Gustavson MD, et al. Evaluation of prognostie and predictive value of mierotubule associated protein tau in two independent cohorts. Breast Cancer Res,2011,13 :85-93. 被引量:1
  • 10Hahn SA,Schutte M,Hoque ATMS,et al.DPC4,a candidate tumor suppressor gene at human chromosome 18q21.1[J].Science,1996,271(5247):350-353. 被引量:1

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部